In support of its New Drug Application (NDA) for govorestat for the treatment of galactosemia, Applied Therapeutics relied on data from its phase 3 ACTION-Galactosemia Kids trial in children ages ...
Hosted on MSN1mon
William Blair Downgrades Applied Therapeutics (APLT)The Company's lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback